药学研究2026，Vol.45Issue(4)：416-423,433,9.DOI:10.13506/j.cnki.jpr.2026.04.009
强直性脊柱炎的发病机制与药物选择
Pathogenesis and drug selection in ankylosing spondylitis
摘要
Abstract
Ankylosing spondylitis(AS)involves the sacroiliac joints and spine,and is more common in young men.Symptoms include lower back pain,morning stiffness,and limited mobility.The etiology is driven by multiple factors including genetics,immune imbalance,and gut microbiota.The current drug therapy mainly uses NSAIDs and TNF-α inhibi-tors,supplemented by DMARDs and glucocorticoids,but the efficacy and tolerability are limited.This article provides an o-verview of the pathogenesis and includes a mechanistic diagram,with a focus on the efficacy and safety of IL-17,IL-23/IL-12,JAK inhibitors,osteogenic pathway inhibitors,intestinal modulators,and small molecule drugs,for reference in new strategies and clinical applications.关键词
强直性脊柱炎/免疫通路/肠道调节剂/综合发病机制/治疗药物/疗效与安全性Key words
Ankylosing spondylitis/Immune pathways/Intestinal modulators/Comprehensive pathogenesis/Therapeutic drugs/Efficacy and safety分类
医药卫生引用本文复制引用
成文静,刘义,许碧莲,李文德..强直性脊柱炎的发病机制与药物选择[J].药学研究,2026,45(4):416-423,433,9.基金项目
国家自然科学基金项目(No.32470567) （No.32470567）
广东省自然科学基金面上项目(No.2023A1515010470) （No.2023A1515010470）
广东省科技计划平台项目(No.2021B1212060002) （No.2021B1212060002）
广东省自然科学基金青年基金项目(No.2023A1515111103) （No.2023A1515111103）
广州市科技计划项目(No.2023B03J1257) （No.2023B03J1257）
